tirzepatide thyroid cancer and papillary Mixed Medullary Carcinoma in a Patient on Mounjaro & Thyroid Cancer Risk: – Do Semaglutide or Tirzepatide cause

In December 2024, the FDA issued a warning letter specifically to Summit Research Peptides for selling unapproved drugs, including semaglutide products marketed as research chemicals

Studies of bariatric surgery patients, who experience rapid weight loss similar to GLP-1 therapy, show that 2040% report temporary amenorrhea (absence of periods) or oligomenorrhea (infrequent periods) in the first six months

maintaining adequate fluid intake and seeking medical advice if symptoms are severe or prolonged is important

Because the dose increases gradually, progress is steady rather than rapid

The secretion of immune cytokines primarily manifests the activation of macrophages